DEP radiopharmaceutical data supports patent application

• DEP® technology shows improved biodistribution
• Patent application filed for radioligand therapy
• Potential for broader oncology applications

Starpharma Holdings Ltd, an innovative biotechnology company, announced the filing of a new patent application supporting its proprietary DEP® technology in radioligand therapy (RLT). The preclinical data indicate that the DEP® platform demonstrates improved biodistribution, with enhanced tumour uptake and retention and reduced off-target accumulation. The findings suggest potential for an improved therapeutic window, with efficient tumour delivery and reduced off-target exposure. The new patent application covers the use of DEP® dendrimer technology in RLT, strengthening Starpharma's platform IP position and supporting its strategy to generate value through the development and partnering of multiple DEP® radiopharmaceutical programs.